Fresenius Medical Care (FME.DE) Stock Price

Fresenius Medical Care Price

XETRA·CLOSED
42.49EUR+0.18 (+0.42 %)
Market closed

Revenue has compounded at 6.0% per year over the past 19 years to 19.63 B EUR. Earnings per share have grown at 4.9% per year over the last 19 years. Fresenius Medical Care's net margin stands at 5.0%, broadly stable from 5.5% several years earlier. Fresenius Medical Care currently offers a dividend yield of about 3.39%. The payout ratio is around 42% of earnings. The dividend has grown at 0.8% per year over the past 19 years. Analysts set a median price target of 46.92 EUR, implying 10.4% above the current price. Of 27 analysts, 11 rate the stock a buy — an overall Hold consensus. The stock trades about 22% above its 52-week low.

Fresenius Medical Care stock price

Volume
Ex-Dividend
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Fresenius Medical Care over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Fresenius Medical Care stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Fresenius Medical Care's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Fresenius Medical Care Stock Price History
DateFresenius Medical Care Price
8/11/202642.49 EUR
8/10/202642.31 EUR
8/7/202642.05 EUR
8/6/202641.88 EUR
8/5/202641.31 EUR
8/4/202641.34 EUR
7/31/202644.45 EUR
7/30/202643.93 EUR
7/29/202643.58 EUR
7/28/202643.19 EUR
7/27/202643.88 EUR
7/24/202643.27 EUR
7/23/202642.43 EUR
7/22/202642.74 EUR
7/21/202643.28 EUR
7/20/202642.27 EUR
7/17/202641.87 EUR
7/16/202642.05 EUR
7/15/202642.12 EUR
7/14/202642.40 EUR
7/13/202642.37 EUR
7/10/202641.93 EUR
7/9/202641.84 EUR
7/8/202641.94 EUR
7/7/202642.29 EUR
7/6/202641.19 EUR
7/3/202640.98 EUR
7/2/202641.15 EUR
7/1/202640.09 EUR
6/30/202639.60 EUR
6/29/202639.56 EUR
6/26/202640.86 EUR
6/25/202640.89 EUR
6/24/202642.15 EUR
6/23/202641.55 EUR
6/22/202641.25 EUR
6/19/202640.97 EUR
6/18/202640.97 EUR
6/17/202640.73 EUR
6/16/202640.65 EUR
6/15/202640.41 EUR
6/12/202639.54 EUR
6/11/202638.92 EUR
6/10/202638.90 EUR
6/9/202638.63 EUR
6/8/202637.87 EUR
6/5/202638.14 EUR
6/4/202637.04 EUR
6/3/202635.63 EUR
6/2/202636.15 EUR
6/1/202636.43 EUR
5/29/202637.54 EUR
5/28/202636.59 EUR
5/27/202637.41 EUR
5/26/202637.68 EUR
5/25/202637.45 EUR
5/22/202637.02 EUR
5/21/202638.97 EUR
5/20/202638.21 EUR
5/19/202638.34 EUR
5/18/202638.12 EUR
5/15/202637.22 EUR
5/14/202636.86 EUR
5/13/202636.53 EUR
5/12/202637.66 EUR
5/11/202637.27 EUR
5/8/202637.34 EUR
5/7/202637.20 EUR
5/6/202635.83 EUR
5/5/202634.72 EUR
5/4/202638.87 EUR
4/30/202638.61 EUR
4/29/202638.07 EUR
4/28/202638.71 EUR
4/27/202638.75 EUR
4/24/202638.84 EUR
4/23/202639.01 EUR
4/22/202639.20 EUR
4/21/202639.60 EUR
4/20/202639.43 EUR
4/17/202639.57 EUR
4/16/202638.95 EUR
4/15/202638.69 EUR
4/14/202639.65 EUR
4/13/202640.02 EUR
4/10/202640.34 EUR
4/9/202640.04 EUR
4/8/202640.25 EUR
4/7/202639.50 EUR
4/2/202638.47 EUR
3/27/202639.41 EUR
3/26/202638.48 EUR
3/24/202637.94 EUR
3/23/202637.50 EUR
3/20/202637.64 EUR
3/19/202638.74 EUR
3/17/202640.02 EUR
3/16/202640.22 EUR
3/13/202639.78 EUR
3/12/202639.81 EUR
3/11/202639.93 EUR
3/10/202639.13 EUR
3/6/202639.72 EUR
3/5/202639.60 EUR
2/27/202639.43 EUR
2/26/202639.08 EUR
2/25/202638.34 EUR
2/23/202641.49 EUR
2/20/202641.07 EUR
2/19/202641.07 EUR
2/18/202640.54 EUR
2/17/202641.37 EUR
2/16/202640.94 EUR
2/14/202641.01 EUR
2/12/202639.92 EUR
2/11/202640.13 EUR
2/10/202640.21 EUR
2/9/202639.72 EUR
2/6/202640.57 EUR
2/5/202640.66 EUR
2/4/202640.16 EUR
2/3/202639.00 EUR
2/2/202638.11 EUR
1/30/202637.61 EUR
1/29/202637.42 EUR
1/28/202637.27 EUR
1/26/202637.34 EUR
1/23/202637.18 EUR
1/22/202637.38 EUR
1/21/202636.11 EUR
1/20/202635.99 EUR
1/19/202636.93 EUR
1/16/202637.28 EUR
1/14/202637.14 EUR
1/13/202639.73 EUR
1/12/202640.72 EUR
1/9/202639.49 EUR
1/8/202639.01 EUR
1/7/202639.65 EUR
1/6/202640.26 EUR
1/5/202640.36 EUR
1/2/202640.09 EUR
12/30/202540.73 EUR
12/29/202540.84 EUR
12/23/202540.80 EUR
12/22/202540.69 EUR
12/19/202540.22 EUR
12/18/202540.29 EUR
12/17/202540.32 EUR
12/16/202540.36 EUR
12/15/202540.41 EUR
12/12/202540.06 EUR
12/11/202539.90 EUR
12/10/202539.82 EUR
12/8/202539.53 EUR
12/5/202540.12 EUR
12/4/202540.73 EUR
12/3/202540.45 EUR
12/2/202540.90 EUR
12/1/202540.97 EUR
11/28/202541.20 EUR
11/27/202541.16 EUR
11/26/202541.28 EUR
11/25/202541.59 EUR
11/24/202541.15 EUR
11/21/202539.61 EUR
11/20/202539.81 EUR
11/19/202539.52 EUR
11/18/202539.61 EUR
11/17/202540.17 EUR
11/14/202540.45 EUR
11/13/202540.85 EUR
11/12/202541.63 EUR
11/10/202541.14 EUR
11/7/202541.46 EUR
11/6/202541.76 EUR
11/5/202541.92 EUR
11/4/202542.77 EUR
11/3/202545.91 EUR
10/31/202547.53 EUR
10/30/202546.94 EUR
10/29/202546.89 EUR
10/28/202546.51 EUR
10/27/202546.69 EUR
10/25/202547.09 EUR
10/23/202546.61 EUR
10/22/202547.04 EUR
10/21/202546.65 EUR
10/20/202546.65 EUR
10/17/202546.34 EUR
10/16/202546.45 EUR
10/15/202546.03 EUR
10/14/202547.34 EUR
10/13/202547.16 EUR
10/10/202547.41 EUR
10/9/202547.36 EUR
10/8/202548.07 EUR
10/7/202545.93 EUR
10/6/202545.72 EUR
10/3/202545.43 EUR
10/2/202545.52 EUR
10/1/202544.86 EUR
9/30/202544.66 EUR
9/29/202543.92 EUR
9/26/202543.67 EUR
9/25/202543.12 EUR
9/24/202544.66 EUR
9/23/202543.85 EUR
9/22/202543.06 EUR
9/19/202543.27 EUR
9/18/202543.30 EUR
9/17/202543.36 EUR
9/16/202542.51 EUR
9/15/202542.20 EUR
9/12/202542.50 EUR
9/11/202542.79 EUR
9/10/202542.55 EUR
9/9/202542.84 EUR
9/8/202542.42 EUR
9/5/202541.95 EUR
9/4/202541.80 EUR
9/3/202541.97 EUR
9/2/202542.09 EUR
9/1/202544.16 EUR
8/29/202543.67 EUR
8/28/202543.27 EUR
8/27/202543.27 EUR
8/26/202543.68 EUR
8/25/202543.65 EUR
8/22/202543.59 EUR
8/21/202543.43 EUR
8/20/202543.28 EUR
8/19/202543.08 EUR
8/18/202542.73 EUR
8/15/202542.79 EUR
8/14/202542.63 EUR
8/13/202542.07 EUR
8/12/202541.46 EUR
Access this data via the Eulerpool API
Get Free API Key

Fresenius Medical Care Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
19.45 B EUR
1.37 B EUR
499.00 M EUR
Jan 1, 2024
19.34 B EUR
1.39 B EUR
537.91 M EUR
Jan 1, 2025
19.63 B EUR
1.83 B EUR
978.00 M EUR
Jan 1, 2026 (e)
19.36 B EUR
1.60 B EUR
1.17 B EUR
Jan 1, 2027 (e)
20.05 B EUR
1.66 B EUR
1.28 B EUR
Jan 1, 2028 (e)
20.88 B EUR
1.73 B EUR
1.46 B EUR
Jan 1, 2029 (e)
21.68 B EUR
1.80 B EUR
1.73 B EUR
Jan 1, 2030 (e)
22.62 B EUR
1.87 B EUR
1.92 B EUR

Fresenius Medical Care Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 12, 2026, 3:24 AM
 
REVENUEB EUR
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEB EUR
EBITB EUR
EBIT MARGIN%
NET INCOMEB EUR
NET INCOME GROWTH%
DIV.EUR
DIV. GROWTH%
SHARESM
20162017201820192020202120222023202420252026e2027e2028e2029e2030e2031e
17.0317.7816.5517.4817.8617.6219.4019.4519.3419.6319.3620.0520.8821.6822.6224.26
11.244.43-6.965.622.19-1.3410.100.28-0.611.52-1.383.604.093.874.327.23
32.2733.7631.1530.8731.0028.8227.3725.3224.6025.6225.6225.6225.6225.6225.6225.62
5.506.005.165.405.545.085.314.934.765.034.965.145.355.565.806.21
2.512.363.040.710.530.301.541.371.391.831.601.661.731.801.87–
14.7313.2818.364.062.961.717.927.047.209.308.298.288.288.288.28–
1.181.281.981.201.160.970.670.500.540.981.171.281.461.731.921.95
25.508.3854.84-39.46-3.00-16.75-30.55-26.007.8382.1219.639.3214.3918.3911.091.20
0.800.961.061.171.202.691.351.121.191.441.491.551.61–––
2.5620.0010.4210.382.56124.17-49.81-17.046.2521.013.474.033.87–––
306.18306.91306.86299.30292.86293.00293.41293.41293.41285.91285.91285.91285.91285.91285.91285.91
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Fresenius Medical Care generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Fresenius Medical Care retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Fresenius Medical Care's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Fresenius Medical Care has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Fresenius Medical Care's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Fresenius Medical Care stock margins

The Fresenius Medical Care margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Fresenius Medical Care. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Fresenius Medical Care.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
28.82 %
1.71 %
5.50 %
Jan 1, 2022
27.37 %
7.93 %
3.47 %
Jan 1, 2023
25.32 %
7.04 %
2.57 %
Jan 1, 2024
24.60 %
7.20 %
2.78 %
Jan 1, 2025
25.62 %
9.31 %
4.98 %
Jan 1, 2026 (e)
25.62 %
8.29 %
6.04 %
Jan 1, 2027 (e)
25.62 %
8.29 %
6.38 %
Jan 1, 2028 (e)
25.62 %
8.29 %
7.01 %

Fresenius Medical Care Stock Revenue, EBIT, Earnings per Share

The Fresenius Medical Care earnings per share therefore indicates how much revenue Fresenius Medical Care has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
60.13 EUR
1.03 EUR
3.31 EUR
Jan 1, 2022
66.11 EUR
5.24 EUR
2.30 EUR
Jan 1, 2023
66.30 EUR
4.67 EUR
1.70 EUR
Jan 1, 2024
65.90 EUR
4.75 EUR
1.83 EUR
Jan 1, 2025
68.65 EUR
6.39 EUR
3.42 EUR
Jan 1, 2026 (e)
65.97 EUR
5.61 EUR
3.99 EUR
Jan 1, 2027 (e)
68.35 EUR
5.81 EUR
4.36 EUR
Jan 1, 2028 (e)
71.15 EUR
6.05 EUR
4.99 EUR

Fresenius Medical Care business model & stock analysis

Fresenius Medical Care AG is a globally leading company in the field of dialysis and kidney care. The company was founded in 1996 when Fresenius AG merged its dialysis business with the US company National Medical Care (NMC). Today, Fresenius Medical Care operates in over 120 countries and employs around 120,000 people. The company operates more than 3,900 dialysis centers worldwide and serves approximately 345,000 dialysis patients. The business model of Fresenius Medical Care aims to improve the lives of patients with chronic kidney diseases by offering high-quality dialysis treatments, kidney care products, and treatment technologies. Fresenius Medical Care provides its patients with a comprehensive range of products and services that range from diagnosis to treatment and enable individualized patient care. A core competency of Fresenius Medical Care is the development and manufacture of dialysis products and technologies. The company offers a wide range of dialysis machines and accessories that can be used to support dialysis care in hospitals, clinics, and dialysis centers. In addition, the company offers medical solutions tailored to the needs of dialysis patients, including artificial kidneys, dialysis filters, and other medical devices. Fresenius Medical Care also conducts extensive research and development activities to develop innovative technologies as well as products and services that can improve the lives of dialysis patients. In terms of diagnostic products, Fresenius Medical Care offers a variety of laboratory and testing solutions that are used to monitor dialysis patients and ensure timely diagnosis of complications and infections. The company also offers a comprehensive range of medical devices and accessories that can be used to support patients in home dialysis. Fresenius Medical Care operates in three business segments: dialysis products, dialysis services, and hospital products. In the dialysis products segment, the company is engaged in the development, manufacture, and distribution of dialysis machines and accessories. In the dialysis services segment, the company operates a variety of dialysis centers and provides dialysis treatments performed by a multidisciplinary team of professionals. The company also operates a network of laboratories that offer diagnostic solutions for dialysis patients. In the hospital products segment, Fresenius Medical Care offers a variety of medical devices and solutions that help improve the clinical care of patients, including apheresis systems, infusion systems, and patient monitors. Throughout its history, Fresenius Medical Care has received numerous awards and recognitions, including the Innovation Award of the state of Baden-Württemberg for the development of an automated dialysis machine that enables better treatment of dialysis patients through the combination of online monitoring systems and intelligent algorithms. Overall, Fresenius Medical Care AG offers a comprehensive range of products and services for dialysis patients and is a significant player in the field of kidney care. The company is committed to improving the quality of life for patients with chronic kidney diseases and driving the development of innovative technologies and methods to treat this disease.

Fresenius Medical Care SWOT Analysis

Strengths

Fresenius Medical Care AG is a global leader in the field of dialysis and renal care, with a strong market presence in over 120 countries. The company benefits from its extensive network of clinics and partnerships, allowing it to provide comprehensive and high-quality services to patients worldwide.

The company's strong financial performance and profitability are key strengths, enabling it to invest in research and development, expand its operations, and attract top talent. Fresenius Medical Care AG's strong brand reputation and recognized expertise further contribute to its competitive advantage in the market.

Weaknesses

Despite its global presence, Fresenius Medical Care AG may face challenges in certain regions due to regulatory and reimbursement constraints. Adapting to diverse regulatory environments and addressing pricing pressures can potentially hinder the company's growth and profitability.

As a specialized healthcare provider, Fresenius Medical Care AG's success heavily relies on the availability of skilled healthcare professionals, efficient supply chain management, and technological advancements. Any weaknesses in these areas may impact the company's ability to deliver consistent and high-quality care to its patients.

Opportunities

The increasing incidence of chronic kidney diseases and the rising aging population present significant growth opportunities for Fresenius Medical Care AG. As the demand for renal care services continues to grow, the company can expand its market share by offering innovative treatment options and enhancing patient experience.

Strategic collaborations and partnerships with healthcare providers, research institutions, and technology companies can also open up new avenues for Fresenius Medical Care AG to develop and deliver advanced dialysis solutions. Additionally, entering emerging markets with underserved renal care needs can fuel the company's expansion and revenue growth.

Threats

Fresenius Medical Care AG operates in a highly competitive industry, facing competition from both established players and emerging entrants. Pricing pressures and the potential loss of key contracts can pose threats to the company's market position and profitability.

Rapid advancements in medical technology and the potential disruption caused by new treatment methods or alternative therapies also present threats to the traditional dialysis market, requiring Fresenius Medical Care AG to adapt and innovate to stay ahead.

Fresenius Medical Care Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Fresenius Medical Care historical P/E ratio, EBIT multiple, and P/S ratio

Fresenius Medical Care annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Fresenius Medical Care shares outstanding

The number of shares of Fresenius Medical Care was 285.91 M in 2025. This indicates how many shares Fresenius Medical Care is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
293.00 M Stocks
Jan 1, 2022
293.41 M Stocks
Jan 1, 2023
293.41 M Stocks
Jan 1, 2024
293.41 M Stocks
Jan 1, 2025
285.91 M Stocks
Jan 1, 2026 (e)
285.91 M Stocks
Jan 1, 2027 (e)
285.91 M Stocks
Jan 1, 2028 (e)
285.91 M Stocks

Fresenius Medical Care stock splits

In Fresenius Medical Care's history, there have been no stock splits.

Fresenius Medical Care Dividend History

28 years of dividend payments · 2 consecutive increases

YearAnnual DividendYoY ChangePayments
20251.44EUR↑ 21.0%1×
May 23, 20251.44EUR↑ 21.0%1/1
20241.19EUR↑ 6.2%1×
20231.12EUR↓ 17.0%1×
20221.35EUR↓ 49.8%1×
20212.69EUR↑ 124.2%2×
20201.20EUR↑ 2.6%1×
20191.17EUR↑ 10.4%1×
20181.06EUR↑ 10.4%1×
20170.96EUR↑ 20.0%1×
20160.80EUR↑ 2.6%1×

Fresenius Medical Care dividend history and estimates

In 2025, Fresenius Medical Care paid a dividend amounting to 1.44 EUR. Dividend means that Fresenius Medical Care distributes a portion of its profits to its owners.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details
Date
Dividend
Dividend (Estimate)
Jan 1, 2021
2.69 EUR
0.00 EUR
Jan 1, 2022
1.35 EUR
0.00 EUR
Jan 1, 2023
1.12 EUR
0.00 EUR
Jan 1, 2024
1.19 EUR
0.00 EUR
Jan 1, 2025
1.44 EUR
0.00 EUR
Jan 1, 2026 (e)
0.00 EUR
1.49 EUR
Jan 1, 2027 (e)
0.00 EUR
1.55 EUR
Jan 1, 2028 (e)
0.00 EUR
1.61 EUR

Fresenius Medical Care dividend payout ratio

In 2025, Fresenius Medical Care had a payout ratio of 42.10%. The payout ratio indicates the percentage of the company's profits that Fresenius Medical Care distributes as dividends.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Payout ratio
Details
Date
Payout ratio
Jan 1, 2021
81.31 %
Jan 1, 2022
58.82 %
Jan 1, 2023
65.86 %
Jan 1, 2024
64.91 %
Jan 1, 2025
42.10 %
Jan 1, 2026 (e)
37.45 %
Jan 1, 2027 (e)
35.52 %
Jan 1, 2028 (e)
32.21 %

Current Fresenius Medical Care forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
4.66 %
Buy
40.74 % (11)
Hold
33.33 % (9)
Sell
25.93 % (7)
12M Price Target
46.92
Last Price
42.31
Currency
EUR
12M Return Potential
10.90 %
LTM Return
0 %

Fresenius Medical Care Analyst Rating Actions

DateFirmActionRatingReliability
10/10/2023
Truist Securities
Truist Securities
MaintainedHold–
7/12/2023
Truist Securities
Truist Securities
MaintainedHold–
5/9/2023
Truist Securities
Truist Securities
MaintainedHold–
4/12/2023
Truist Securities
Truist Securities
MaintainedHold–
2/22/2023
Truist Securities
Truist Securities
MaintainedHold–
6/21/2022
Truist Securities
Truist Securities
MaintainedHold–
11/23/2021
HSBC
HSBC
MaintainedHold–
11/17/2021
RBC Capital
RBC Capital
MaintainedSector PerformPerform52
11/16/2021
RBC Capital
RBC Capital
MaintainedSector Perform52
11/10/2021
Jefferies
Jefferies
UpgradeUnderperformHold47

Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.

Fresenius Medical Care Earnings Calls

2025

Fresenius Medical Care Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
2/20/20230.69EUR-5.28 BEUR-2022 Q4
10/30/20220.68EUR-5.12 BEUR-2022 Q3
7/28/20220.83EUR-4.84 BEUR-2022 Q2
5/4/20220.70EUR-4.54 BEUR-2022 Q1
2/22/20220.88EUR-4.68 BEUR-2021 Q4
11/2/20210.92EUR-4.54 BEUR-2021 Q3
7/30/20210.76EUR-4.38 BEUR-2021 Q2
5/6/20210.80EUR-4.29 BEUR-2021 Q1
2/23/20211.21EUR-4.52 BEUR-2020 Q4
10/29/20201.16EUR-4.46 BEUR-2020 Q3
...

EESG©

Eulerpool ESG Scorecard© for the Fresenius Medical Care stock

81/100
70
Environment
86
Social
88
Governance
E

Environment

20
Scope 1 - Direct Emissions360,803
Scope 2 - Indirect emissions from purchased energy450,611
Scope 3 - Indirect emissions within the value chain2,993,388
Total CO₂ emissions811,414
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides—
Palm Oil
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees70
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Fresenius Medical Care shareholder structure

% Name
0.00310%
GENERALI INVESTMENTS CEE, INVESTICNI SPOLECNOST, A.S.
GENERALI INVESTMENTS CEE, INVESTICNI SPOLECNOST, A.S.

Fresenius Medical Care Beneficial Ownership Filings (SEC 13D/G)

Free Float
68.4%
Float Shares
-
Shares Outstanding
-

Fresenius Medical Care Executives and Management Board

18 members · avg. age 57 · 39 % women

HG

Ms. Helen Giza (57)

Chairman of the Management Board, Chief Executive Officer

4.44 M EUR

Management

CC

Mr. Craig Cordola (54)

Member of the Management Board, Chief Executive Officer - Care Delivery

3.72 M EUR
KM

Dr. Katarzyna Mazur-Hofsaess (62)

Member of the Management Board, Chief Executive Officer - Care Enablement

3.28 M EUR
FM

Dr. Frank Maddux (68)

Member of the Management Board, Global Chief Medical Officer

2.76 M EUR
MF

Mr. Martin Fischer (49)

Chief Financial Officer, Member of the Management Board

2.52 M EUR
DH

Dr. Dominik Heger

Head of Investor Relations, Strategic Development and Communications, EVP · since 2019

–

Board of Directors

JH

Dr. Joerg Haering (55)

Member of the Management Board - Legal, Compliance, Human Resources and Labor Relations Director

1.38 M EUR
MS

Mr. Michael Sen (57)

Chairman of the Supervisory Board · since 2023

509,000.00 EUR
SB

Ms. Stefanie Balling (56)

Vice Chairman of the Supervisory Board, Employee Representatives · since 2024

320,000.00 EUR
PW

Ms. Pascale Witz (58)

Independent Member of the Supervisory Board

299,000.00 EUR
MK

Dr. Marcus Kuhnert (57)

Independent Member of the Supervisory Board

297,000.00 EUR
SK

Mr. Shervin Korangy (51)

Independent Member of the Supervisory Board

245,000.00 EUR

Frequently asked questions about Fresenius Medical Care

Fresenius Medical Care AG is a leading global provider of dialysis products, services, and solutions for patients with chronic kidney failure. The company's business model revolves around providing high-quality dialysis care to patients in over 120 countries. Fresenius Medical Care AG offers a comprehensive range of dialysis machines, dialyzers, and other related products to ensure efficient and effective treatment. Furthermore, the company operates a network of dialysis clinics, providing personalized care for patients worldwide. With a focus on innovation, research, and development, Fresenius Medical Care AG continuously strives to enhance patient outcomes and improve the overall quality of life for individuals with kidney disease.

Fresenius Medical Care AG is primarily active in the healthcare industry.

The main competitors of Fresenius Medical Care AG in the market are DaVita Inc., Baxter International Inc., and B. Braun Melsungen AG.

Fresenius Medical Care AG is a leading global healthcare company specializing in dialysis products and services. Established in 1996, it stemmed from the merger of Fresenius AG and National Medical Care. With its headquarters in Germany, the company has expanded its reach worldwide, operating in nearly 150 countries. Fresenius Medical Care AG is renowned for its expertise in renal therapy, offering innovative dialysis machines, dialyzers, and related medical supplies. As a market leader, it provides life-saving treatments to millions of people suffering from chronic kidney disease. The company's commitment to delivering high-quality care and advancing renal healthcare has made Fresenius Medical Care AG a trusted name in the medical industry.

Fresenius Medical Care AG, a leading healthcare company, has achieved significant milestones throughout its history. It pioneered the development of advanced dialysis products and services, revolutionizing the treatment of end-stage renal disease. The company has established a global presence, operating in over 120 countries and serving millions of patients worldwide. Additionally, Fresenius Medical Care AG has continuously expanded its business through strategic acquisitions and collaborations, strengthening its position as a market leader in dialysis care. With a commitment to research and development, the company has achieved breakthrough innovations in dialysis technology, enhancing patient outcomes and quality of life. Overall, Fresenius Medical Care AG’s impressive achievements have solidified its reputation as a trusted provider of renal therapies.

Fresenius Medical Care AG is primarily present in various countries and regions across the globe. With a strong global presence, the company operates in more than 150 countries and regions, including the United States, Germany, Asia-Pacific, Latin America, and Europe. Its widespread international network enables Fresenius Medical Care AG to provide advanced renal care products, services, and solutions to patients worldwide. As the global leader in dialysis and kidney care, Fresenius Medical Care AG continues to expand its reach and impact, ensuring quality healthcare for patients globally.

Fresenius Medical Care AG represents values of quality, innovation, and patient-centered care. With a dedicated corporate philosophy, the company focuses on providing life-saving dialysis products, therapies, and services to patients worldwide. The commitment to excellence, compassion, and continuous advancement in medical technology enables Fresenius Medical Care AG to enhance patients' quality of life and deliver optimal renal care. As a global leader in the field, Fresenius Medical Care AG maintains a strong emphasis on scientific research, sustainability, and delivering efficient healthcare solutions for patients suffering from chronic kidney diseases.

Analysts currently set an average price target of 45.79 EUR for the Fresenius Medical Care stock (median: 46.92 EUR), implying +8.2 % versus the latest price. The consensus is based on 27 analyst ratings.

Fresenius Medical Care Analyst Price Targets 2026

27 analysts currently rate the Fresenius Medical Care stock: 11 recommend buying, 9 holding and 7 selling. For 2026, analysts expect Fresenius Medical Care to generate revenue of 19.36 B EUR and earnings per share of 4.09 EUR.

Fresenius Medical Care Analyst Price Targets 2026

The Fresenius Medical Care share (FME.DE) is listed on 10 stock exchanges, including: XETRA (FME.DE), Frankfurt (FME.F), München (FME.MU), Düsseldorf (FME.DU), Hamburg (FME.HM), London (0H9X.L), SIX (Zürich) (FMEEUR.SW), Wien (FME.VI).

Fresenius Medical Care AG is a leading provider of products and services for the dialysis treatment of patients with kidney failure. The company is headquartered in Bad Homburg, Germany, and operates in over 120 countries worldwide. Fresenius Medical Care also operates its own dialysis centers and offers various other medical services. The business model of Fresenius Medical Care includes three business segments: dialysis products, services related to dialysis treatment, and the care of patients with chronic diseases. In the field of dialysis products, Fresenius Medical Care develops and produces a wide range of dialysis equipment and reagents. These products are sold to both their own dialysis centers and other medical facilities worldwide. Thanks to technological innovations in dialysis treatment, medical professionals can offer patients better outcomes and a higher quality of life. In the second business segment, Fresenius Medical Care provides services related to dialysis treatment. The company operates and manages its own dialysis centers and also provides the necessary medical professionals. Additionally, Fresenius Medical Care offers technical support and training for the use of their own dialysis products. These services are an important part of the business model as they ensure both the sales of their own products and the high-quality medical care of patients. A third business segment of Fresenius Medical Care is the care of patients with chronic diseases. Through the use of data analysis and telemedicine technologies, medical professionals from Fresenius Medical Care can actively care for patients - both online and through home visits. The goal is to improve the health of patients and avoid hospital stays. The business model of Fresenius Medical Care is based on preventive health care and support for people with chronic diseases such as kidney failure. By providing high-quality products and services and establishing a comprehensive patient care program, Fresenius Medical Care strengthens its position as a leading provider in dialysis treatment. In recent years, Fresenius Medical Care has also increased its investment in research and development of innovative treatment methods to continuously improve the quality of medical care for patients with chronic diseases. The extensive expertise in this field enables the development of new treatment modalities, including digital solutions, that benefit patients. Overall, Fresenius Medical Care is an innovative company specializing in the provision of products and services for dialysis treatment. By combining technological innovations, a comprehensive patient care program, and a constant focus on the needs of medical professionals in the global healthcare industry, the company relies on a forward-looking, promising business model in a sector of growing importance.

The expected revenue of Fresenius Medical Care is 19.36 B EUR. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Fresenius Medical Care is 1.17 B EUR. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Fresenius Medical Care is currently 10.38. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Fresenius Medical Care stock.

The price-to-sales ratio (P/S) of Fresenius Medical Care is currently 0.63. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Fresenius Medical Care stock.

The Eulerpool Quality Score for Fresenius Medical Care is 4/10.

The ISIN of Fresenius Medical Care is DE0005785802. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Fresenius Medical Care is 578580. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Fresenius Medical Care is FME.DE. The ticker symbol is used to trade Fresenius Medical Care shares on the stock exchange.

Over the past 12 months, Fresenius Medical Care paid a dividend of 1.44 EUR . This corresponds to a dividend yield of about 3.39 %. For the coming 12 months, Fresenius Medical Care is expected to pay a dividend of 1.55 EUR.

The current dividend yield of Fresenius Medical Care is 3.39 %.

Fresenius Medical Care pays a dividend, distributed in the months of , , , .

Fresenius Medical Care paid dividends every year for the past 28 years.

For the upcoming 12 months, dividends amounting to 1.55 EUR are expected. This corresponds to a dividend yield of 3.66 %.

Fresenius Medical Care is assigned to the 'Health' sector.

To receive the latest dividend of Fresenius Medical Care from amounting to 1.44 EUR, you needed to have the stock in your portfolio before the ex-date on .

The last dividend was paid out on .

In the year 2025, Fresenius Medical Care distributed 1.19 EUR as dividends.

The dividends of Fresenius Medical Care are distributed in EUR.

All fundamentals and in-depth analysis of Fresenius Medical Care

Our stock analysis for Fresenius Medical Care stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Fresenius Medical Care. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Fresenius Medical Care Stock
Fresenius Medical Care Revenue→
Fresenius Medical Care Stock
Fresenius Medical Care Net Income→
Fresenius Medical Care Stock
Fresenius Medical Care P/E→
Fresenius Medical Care Stock
Fresenius Medical Care P/S→
Fresenius Medical Care Stock
Fresenius Medical Care EBIT→
Fresenius Medical Care Stock
Fresenius Medical Care Dividend→
Fresenius Medical Care Stock
Fresenius Medical Care Directors Dealings→
Fresenius Medical Care Stock
Fresenius Medical Care Stocks→
Fresenius Medical Care Stock
Fresenius Medical Care Market capitalization→
Fresenius Medical Care Stock
Fresenius Medical Care Debt→
Fresenius Medical Care Stock
Fresenius Medical Care Liabilities→
Fresenius Medical Care Stock
Fresenius Medical Care Equity→
Fresenius Medical Care Stock
Fresenius Medical Care AAQS→
Fresenius Medical Care Stock
Fresenius Medical Care Employees→
Fresenius Medical Care Stock
Fresenius Medical Care ROE→
Fresenius Medical Care Stock
Fresenius Medical Care ROA→
Fresenius Medical Care Stock
Fresenius Medical Care ROCE→
Fresenius Medical Care Stock
Fresenius Medical Care News→
Fresenius Medical Care Stock
Fresenius Medical Care Analyst Price Targets→

Health Stocks

Fresenius Medical CareFreliiFresenius SE & Co KGaAFredun PharmaceuticalsFrontier BiotechnologiesFrance Bed Holdings CoFuan Pharmaceutical Group CoForza InnovationsFuji Pharma CoFortress BiotechFujian Cosunter Pharmaceutical CoFortrea HoldingsAll Stocks A–Z →